Pacer Advisors Inc. Boosts Stock Position in Medpace Holdings, Inc. $MEDP

Pacer Advisors Inc. raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 38.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 153,652 shares of the company’s stock after acquiring an additional 42,362 shares during the quarter. Pacer Advisors Inc. owned approximately 0.54% of Medpace worth $86,299,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Optiver Holding B.V. purchased a new position in Medpace in the 3rd quarter worth about $27,000. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. purchased a new stake in Medpace in the 4th quarter valued at about $30,000. Elyxium Wealth LLC purchased a new stake in Medpace in the 4th quarter valued at about $30,000. Finally, Quarry LP bought a new position in Medpace in the 3rd quarter worth about $35,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Transactions at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 20.50% of the company’s stock.

Medpace Stock Up 0.7%

NASDAQ MEDP opened at $460.20 on Friday. The firm has a market cap of $13.14 billion, a PE ratio of 28.93, a price-to-earnings-growth ratio of 2.32 and a beta of 1.18. Medpace Holdings, Inc. has a 52 week low of $301.90 and a 52 week high of $628.92. The company has a 50 day moving average price of $453.33 and a 200 day moving average price of $499.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same period in the prior year, the firm posted $3.67 earnings per share. The business’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. BMO Capital Markets lowered their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Royal Bank Of Canada reduced their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Robert W. Baird decreased their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Barclays lowered their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Finally, Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $467.08.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.